Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 139 publications
Predictors of Rehabilitation Utilization After CAR T-Cell Therapy.
Journal: Transplantation and cellular therapy
Published: April 29, 2026
Implementation of a Multidisciplinary Eye Clinic within a Cancer Center for Patients at Risk of Ocular Graft versus Host Disease.
Journal: Ophthalmology science
Published: February 10, 2026
Beyond the typical immune effector cell-associated neurotoxicity syndrome: Characterizing non-immune effector cell-associated neurotoxicity syndrome neurological complications in chimeric antigen receptor T-cell therapy-A retrospective analysis.
Journal: Neuro-oncology advances
Published: February 09, 2026
CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study.
Journal: Cancer research communications
Published: December 17, 2025
Real-World Experience With a ZUMA-1 Cohort 4 Adopted Approach to CRS and ICANS in CAR-T Recipients.
Journal: European journal of haematology
Published: October 20, 2025
CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma.
Journal: Haematologica
Published: August 01, 2025
Obecabtagene autoleucel, a novel CD19-directed CAR T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: the future for reducing toxicity and T-cell exhaustion?
Journal: Expert review of hematology
Published: June 23, 2025
An interview with Dr. Jean A. Yared on his experience as an investigator for obecabtagene autoleucel - by Reegan Burnell-Clarke (Commissioning Editor).
Journal: Expert review of hematology
Published: June 23, 2025
RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT.
Journal: Blood
Published: April 14, 2025
Efficacy of Total-Body Irradiation-based Intensified Myeloablative Regimens for Acute Leukemia-An International Collaborative Study.
Journal: EJHaem
Published: April 03, 2025
Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas.
Journal: Blood neoplasia
Published: March 10, 2025
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma.
Journal: Nature communications
Published: December 10, 2024
Last Updated: 09/26/2026